GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Current Deferred Revenue

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Current Deferred Revenue : CHF0.0 Mil (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Cosmo Pharmaceuticals NV's current deferred revenue for the quarter that ended in Jun. 2023 was CHF0.0 Mil.

Cosmo Pharmaceuticals NV Current Deferred Revenue Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Current Deferred Revenue Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cosmo Pharmaceuticals NV Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Current Deferred Revenue
Comparable Companies
BSP:GGBR4 BSP:CMIN3 BSP:GOAU3 BSP:FESA3 BSP:PATI3 LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4519 TSE:4568
Traded in Other Exchanges
CMOPF:USA C43:Germany COPN:Switzerland
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Website
https://www.cosmopharma.com
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines